Steven R. Goldstein is an American inventor, author and a tenured professor of obstetrics and gynecology at New York University Grossman School of Medicine.
After graduating from the New York University School of Medicine in 1975, he completed an internship in obstetrics and gynecology at Parkland Memorial Hospital in Dallas, Texas from 1975-1976.
He also maintains a half-time private practice as a generalist in obstetrics and gynecology and is affiliated with at NYU Langone Medical Center.
Clinically, his practice has evolved, focusing more on menopausal and perimenopausal medicine with particular emphasis in ultrasound applications both for adnexal masses and abnormal bleeding.
[4] In 2019, he received the Joseph H. Holmes Clinical Pioneer Award from the American Institute of Ultrasound in Medicine (AIUM).
He was also first to warn against unnecessary biopsy in nonbleeding postmenopausal patients with an incidental finding of thick endometrial lining on vaginal sonogram.
He has been on gynecologic advisory boards and/or consulted for Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Merck, GlaxoSmithKline, Novo Nordisk, Wyeth, Procter & Gamble, Warner Chilcott, Shionogi, QuatRx, Depomed, and Pfizer.
He has represented Eli Lilly, Forendo, Astellas Pharm, Acella Pharmaceuticals, Scynexis, Myovant Sciences, Avion Pharmaceuticals, L'Oréal, Cosmetique Active, Vichy, Peppy, Cooper Surgical, AbbVie, Mithra, Mylan, Shield, Pfizer and Mirabilis Medical and their appearances before FDA Advisory Boards.